Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response

Yu‐Ting Jiang; Kai‐Hua Chen; Zhong‐Guo Liang; Jie Yang; Song Qu; Ling Li; Xiao‐dong Zhu

doi:10.1002/cam4.5256

journal article Open Access Sep 20, 2022

Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response

Yu‐Ting Jiang

Kai‐Hua Chen

Zhong‐Guo Liang Jie Yang

Song Qu

Ling Li

Xiao‐dong Zhu

Cancer Medicine Vol. 12 No. 4 pp. 4010-4022 · Wiley

View at Publisher Save 10.1002/cam4.5256

Abstract

AbstractBackgroundThe optimal number of cycles of induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (LANPC) is unclear. We aimed to combine the tumor response during IC and tumor stage to individualize the number of IC cycles.MethodsTotally, 498 LANPC patients who received IC plus CCRT between 2014 and 2018 were reviewed. Tumor response during IC was used to stratify patients with different risks. All patients were classified into those who received two cycles of IC and those who were treated with three cycles. Propensity score matching methods were performed to compare the treatment efficiency.ResultsAfter two cycles of IC, 340/498 (68.3%) cases showed complete tumor response (CR)/partial response (PR) and 158 (31.7%) achieved stable disease (SD)/disease progression (PD). Unfavorable responders (SD/PD) exhibited poor survival outcomes. The three‐cycle IC regimen was correlated with better OS and PFS than the two‐cycle regimen for N2‐3 patients in the CR/PR group. However, the use of different IC cycle strategies achieved similar survival outcomes for SD/PD or N0‐1 patients. The incidences of acute toxicities were higher in the IC = 3 group.ConclusionsTumor response during IC could be a powerful predictor of LANPC and could be used to guide the individualized number of IC cycles. A three‐cycle IC regimen seemed to be preferable for N2‐3 patients who received CR/PR during IC. However, an additional cycle of IC could not benefit N0‐1 or SD/PD patients, and the optimal treatment strategies for these patients require further consideration.

Topics

No keywords indexed for this article. Browse by subject →

References

46

[1]

Nasopharyngeal carcinoma

Yu-Pei Chen, Anthony T C Chan, Quynh-Thu Le et al.

The Lancet 10.1016/s0140-6736(19)30956-0

[2]

10.1016/j.ijrobp.2008.07.062

[3]

10.1002/cncr.29795

[4]

10.4143/crt.2020.899

[5]

10.1200/jco.2001.19.23.4305

[6]

10.1200/jco.2008.18.1545

[7]

10.1016/j.radonc.2013.10.020

[8]

Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial

Ying Sun, Wen-Fei Li, Nian-Yong Chen et al.

The Lancet Oncology 10.1016/s1470-2045(16)30410-7

[9]

Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Yu-Pei Chen, Nofisat Ismaila, Melvin L.K. Chua et al.

Journal of Clinical Oncology 10.1200/jco.20.03237

[10]

10.6004/jnccn.2020.0031

[11]

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial

Su-Mei Cao, Qi Yang, Ling Guo et al.

European Journal of Cancer 10.1016/j.ejca.2016.12.039

[12]

10.1093/annonc/mdx770

[13]

Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma

Yuan Zhang, Lei Chen, Guo-Qing Hu et al.

New England Journal of Medicine 10.1056/nejmoa1905287

[14]

10.18632/oncotarget.21587

[15]

10.1002/hed.26141

[16]

10.1016/j.oraloncology.2016.10.014

[17]

10.1016/j.radonc.2019.04.020

[18]

10.1016/j.radonc.2020.10.005

[19]

10.1038/srep24835

[20]

10.3389/fonc.2021.683475

[21]

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E.A. Eisenhauer, P. Therasse, J. Bogaerts et al.

European Journal of Cancer 10.1016/j.ejca.2008.10.026

[22]

Kuss O "Propensity score: an alternative method of analyzing treatment effects" Dtsch Arztebl Int (2016)

[23]

10.1213/ane.0000000000002787

[24]

10.21147/j.issn.1000-9604.2018.01.06

[25]

10.7150/jca.65315

[26]

10.1016/j.radonc.2021.08.010

[27]

Prognostic value of wait time in nasopharyngeal carcinoma treated with intensity modulated radiotherapy: a propensitymatched analysis

Yu-Pei Chen, Yan-Ping Mao, Wen-Na Zhang et al.

Oncotarget 10.18632/oncotarget.7789

[28]

Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer

Shu‐Hui Lee, Pei‐Hung Chang, Ping‐Tsung Chen et al.

Cancer Medicine 10.1002/cam4.2254

[29]

Survival impact of waiting time for radical radiotherapy in nasopharyngeal carcinoma: A large institution-based cohort study from an endemic area

Hu Liang, Yanyun Xiang, Xing Lv et al.

European Journal of Cancer 10.1016/j.ejca.2016.12.009

[30]

10.21037/cco.2018.04.05

[31]

10.7150/thno.19710

[32]

10.1002/prca.200800164

[33]

10.1159/000065061

[34]

10.1016/j.humpath.2007.10.009

[35]

10.1038/onc.2012.294

[36]

10.1158/1078-0432.ccr-17-2656

[37]

10.21037/atm.2019.02.15

[38]

10.1186/s12885-020-6555-7

[39]

10.1016/j.oraloncology.2019.08.001

[40]

10.1634/theoncologist.2016-0105

[41]

10.1002/cncr.31741

[42]

10.1016/j.ijrobp.2019.01.007

[43]

10.1016/j.ijrobp.2015.08.003

[44]

10.3389/fonc.2019.01343

[45]

10.1158/1078-0432.ccr-12-3702

[46]

10.1093/jnci/djx007

Cited By

10

Combined Real-time Liquid Biopsy With TNM Stage to Guide Induction Chemotherapy Cycles in Nasopharyngeal Carcinoma: A Development and Validation Study

Pengjie Ji, Jiaxi Shen · 2026

International Journal of Radiation...

Metrics

10

Citations

46

References

Details

Published: Sep 20, 2022
Vol/Issue: 12(4)
Pages: 4010-4022
License: View

Authors

Y

Yu‐Ting Jiang

Department of Radiation Oncology Guangxi Medical University Cancer Hospital Nanning China

K

Kai‐Hua Chen

Department of Radiation Oncology Guangxi Medical University Cancer Hospital Nanning China

Z

Zhong‐Guo Liang

Department of Radiation Oncology Guangxi Medical University Cancer Hospital Nanning China

J

Jie Yang

Department of Radiation Oncology Guangxi Medical University Cancer Hospital Nanning China

S

Song Qu

Department of Radiation Oncology Guangxi Medical University Cancer Hospital Nanning China; Key Laboratory of Early Prevention and Treatment for Regional High‐Incidence‐ Tumor Guangxi Medical University, Ministry of Education Nanning China

L

Ling Li

Department of Radiation Oncology Guangxi Medical University Cancer Hospital Nanning China; Key Laboratory of Early Prevention and Treatment for Regional High‐Incidence‐ Tumor Guangxi Medical University, Ministry of Education Nanning China

X

Xiao‐dong Zhu

Department of Radiation Oncology Guangxi Medical University Cancer Hospital Nanning China; Key Laboratory of Early Prevention and Treatment for Regional High‐Incidence‐ Tumor Guangxi Medical University, Ministry of Education Nanning China; Department of Oncology Affiliated Wuming Hospital of Guangxi Medical University Nanning China

Funding

Guangxi Medical University Award: GXMUYSF20212

Cite This Article

Yu‐Ting Jiang, Kai‐Hua Chen, Zhong‐Guo Liang, et al. (2022). Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response. Cancer Medicine, 12(4), 4010-4022. https://doi.org/10.1002/cam4.5256

Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response

You May Also Like